^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    Apply
    Assessing the Immunogenicity of pING-hHER3FL (NCT03832855)
    Phase 1
    Herbert Lyerly
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/13/2020
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    ERBB3
    |
    ERBB3 expression
    |
    pING-hHER3FL
    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (NCT03173937)
    Phase 1/2
    National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/13/2017
    Primary completion :
    04/28/2025
    Completion :
    03/01/2028
    CD34 • HLA-B • HLA-C
    |
    Omisirge (omidubicel)
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (NCT05078866)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/10/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    BRAF mutation
    |
    NOUS-209
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (NCT05419011)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    05/08/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects (FLAMINGO-01) (NCT05232916)
    Phase 3
    Greenwich LifeSciences, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/11/2022
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2 • HLA-A
    |
    HLA-A*02 positive
    |
    Herceptin (trastuzumab) • GLSI-100 • GP2
    Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (NCT04287868)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/09/2020
    Primary completion :
    07/26/2022
    Completion :
    07/01/2026
    PD-L1 • CDKN2A • CD4
    |
    PD-L1 negative
    |
    bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC
    Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release (IOV-EAP 402) (NCT05398640)
    Phase N/A
    Iovance Biotherapeutics, Inc.
    Available
    Last update posted :
    02/17/2025
    PD-L1
    |
    Amtagvi (lifileucel)
    Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer (CIP2023-001) (NCT06366490)
    Phase 1
    PhotonPharma, Inc.
    Not yet recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/30/2025
    Primary completion :
    12/30/2025
    Completion :
    06/30/2026
    MUC16
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    11/05/2015
    Primary completion :
    01/25/2018
    Completion :
    07/01/2025
    HLA-DRB1
    |
    Triplex (CMV-MVA vaccine)
    Adjuvant Therapy with an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (CASE6119) (NCT04674306)
    Phase 1
    George T. Budd
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/01/2021
    Primary completion :
    05/01/2025
    Completion :
    11/01/2025
    HER-2 • ER • PGR • BRCA1 • PRL
    |
    HER-2 negative • PALB2 mutation • ER negative
    |
    alpha-lactalbumin vaccine
    Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (SAKK 66/17) (NCT03993678)
    Phase 1/2
    Swiss Group for Clinical Cancer Research
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/12/2020
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    BRAF
    |
    BRAF mutation
    |
    IP-001
    Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma (BNT111-01) (NCT04526899)
    Phase 2
    BioNTech SE
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    05/19/2021
    Primary completion :
    01/25/2024
    Completion :
    07/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • BNT111
    Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma (NCT05628883)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    11/22/2022
    Primary completion :
    12/01/2025
    Completion :
    12/31/2026
    BRAF • IL2
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • TIDAL-01
    A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia (NCT05672355)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/01/2023
    Primary completion :
    01/12/2026
    Completion :
    01/12/2026
    IFNG
    Combination Study of SV-BR-1-GM With Retifanlimab (BRI-ROL-001) (NCT03328026)
    Phase 1/2
    BriaCell Therapeutics Corporation
    Enrolling by invitation
    Last update posted :
    02/04/2025
    Initiation :
    03/16/2018
    Primary completion :
    11/03/2025
    Completion :
    11/30/2028
    ER • PIK3CA • PGR
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous
    Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer (IRB00210915) (NCT04117087)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    05/28/2020
    Primary completion :
    08/08/2025
    Completion :
    08/08/2025
    KRAS • CD8 • CD4
    |
    KRAS mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Hiltonol (poly-ICLC) • KRAS peptide vaccine
    GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC (GT-30) (NCT04251117)
    Phase 1/2
    Geneos Therapeutics
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/01/2020
    Primary completion :
    11/29/2024
    Completion :
    11/29/2028
    IFNG
    |
    Keytruda (pembrolizumab) • rocakinogene sifuplasmid (INO-9012) • GNOS-PV02
    Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer (NCT05539365)
    Phase 2
    Roswell Park Cancer Institute
    Withdrawn
    Last update posted :
    01/29/2025
    Initiation :
    02/01/2025
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    PD-L1
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • aDC1 vaccine
    Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA (FusionVAC22_02) (NCT06789198)
    Phase 1
    University Hospital Tuebingen
    Not yet recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/01/2025
    Primary completion :
    11/01/2028
    Completion :
    11/01/2028
    IFNG
    |
    DNAJB1-PRKACA peptide vaccine • Fusion-VAC-XS15
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) (NCT03313778)
    Phase 1
    ModernaTX, Inc.
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    08/14/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • ALK • TMB
    |
    EGFR mutation • ALK positive • ALK translocation • EGFR positive
    |
    Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)
    Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer (NCT06782932)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Not yet recruiting
    Last update posted :
    01/20/2025
    Initiation :
    04/01/2025
    Primary completion :
    12/01/2028
    Completion :
    12/01/2028
    CD20
    |
    cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine
    CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer (HEMONC CIRM IST Lung) (NCT03546361)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    07/08/2019
    Primary completion :
    01/11/2026
    Completion :
    01/11/2027
    PD-L1
    |
    EGFR mutation • EGFR T790M • ALK rearrangement
    |
    Keytruda (pembrolizumab) • Ad-CCL21-DC
    Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (NATASHA) (NCT05325632)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    12/24/2024
    Initiation :
    10/28/2021
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    HER-2
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
    Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC (VERSATILE-002) (NCT04260126)
    Phase 2
    PDS Biotechnology Corp.
    Active, not recruiting
    Last update posted :
    12/18/2024
    Initiation :
    03/29/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Versamune HPV
    Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma (KEYNOTE-E72) (NCT06016920)
    Phase 1/2
    Nykode Therapeutics ASA
    Recruiting
    Last update posted :
    12/17/2024
    Initiation :
    12/19/2023
    Primary completion :
    09/01/2027
    Completion :
    01/01/2028
    PD-L1 • IFNG
    |
    Keytruda (pembrolizumab) • VB10.16
    DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE) (NCT04106115)
    Phase 1/2
    University College, London
    Recruiting
    Last update posted :
    12/04/2024
    Initiation :
    03/25/2022
    Primary completion :
    05/31/2025
    Completion :
    05/31/2029
    PD-L1
    |
    HLA-A*02:01 • HLA-A*02
    |
    Imfinzi (durvalumab) • S-588210
    Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors (KEYNOTE-E58) (NCT04041310)
    Phase 1/2
    Nouscom SRL
    Active, not recruiting
    Last update posted :
    11/20/2024
    Initiation :
    10/21/2019
    Primary completion :
    04/30/2025
    Completion :
    11/30/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • NOUS-209
    A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas (NCT06660056)
    Phase 1
    GONGCHU Biotechnology Co., Ltd
    Recruiting
    Last update posted :
    10/26/2024
    Initiation :
    10/08/2024
    Primary completion :
    02/08/2026
    Completion :
    08/08/2026
    PD-1 • IFNG • IL6 • TNFA • CD4 • IL10
    Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years (NCT04895982)
    Phase 2
    BioNTech SE
    Completed
    Last update posted :
    10/09/2024
    Initiation :
    10/15/2021
    Primary completion :
    07/23/2023
    Completion :
    07/23/2023
    EGFR • BRAF • ROS1 • BCL2 • NTRK
    Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer (NCT05617040)
    Phase 1/2
    Barinthus Biotherapeutics
    Active, not recruiting
    Last update posted :
    10/01/2024
    Initiation :
    01/30/2023
    Primary completion :
    08/01/2026
    Completion :
    04/01/2027
    MSI • CD8 • CD4
    |
    FOLH1 positive
    A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy (NCT04847050)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/27/2024
    Initiation :
    04/28/2021
    Primary completion :
    05/25/2023
    Completion :
    05/25/2023
    PD-1
    A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer (NCT06471673)
    Phase 1/2
    BriaCell Therapeutics Corporation
    Recruiting
    Last update posted :
    08/26/2024
    Initiation :
    05/29/2024
    Primary completion :
    04/30/2025
    Completion :
    10/30/2025
    PD-L1 • PD-L2 • PRAME
    |
    Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Bria-OTS
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (NCT05264974)
    Phase 1
    University of Florida
    Suspended
    Last update posted :
    06/13/2024
    Initiation :
    06/01/2024
    Primary completion :
    09/01/2026
    Completion :
    09/01/2026
    BRAF
    |
    BRAF wild-type
    |
    RNA-NP vaccine
    Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC) (NCT06072612)
    Phase 3
    BriaCell Therapeutics Corporation
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    12/05/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    ER • PGR
    |
    HER-2 negative
    |
    carboplatin • capecitabine • cyclophosphamide • Halaven (eribulin mesylate) • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)
    Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (GENUINE) (NCT05286060)
    Phase 2
    Yonsei University
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    03/01/2022
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)
    Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. (NCT06099418)
    Phase 2
    Nykode Therapeutics ASA
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    04/18/2024
    Primary completion :
    05/01/2027
    Completion :
    05/01/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • VB10.16
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT02068794)
    Phase 1/2
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    03/31/2014
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    CD4
    |
    MV-NIS
    A Study to Investigate LYL845 in Adults With Solid Tumors (NCT05573035)
    Phase 1
    Lyell Immunopharma, Inc.
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    12/19/2022
    Primary completion :
    08/01/2025
    Completion :
    09/01/2027
    BRAF • MSI
    |
    MSI-H/dMMR • BRAF mutation
    |
    LYL845
    Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) (NCT05269381)
    Phase 1/2
    Mayo Clinic
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    03/31/2022
    Primary completion :
    02/24/2025
    Completion :
    02/24/2026
    KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK
    |
    TMB-H
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine
    A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (NCT03912064)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/10/2019
    Primary completion :
    05/24/2024
    Completion :
    07/01/2024
    IL2RA • ISG20
    |
    Yervoy (ipilimumab) • CD25hi Treg depleted DLI